分析：从MR上看，肿瘤起源于脑干背侧，髓母细胞瘤可能性较小。故病理性质上多考虑胶质瘤可能性大（弥漫中线胶质瘤，室管膜瘤等）。考虑到该占位已对脑干产生明显压迫，同时导致脑积水，故手术切除为优先选择；替代方案为脑室腹腔分流同时行肿瘤活检。

Results from the Phase II C-144-01 trial showed that a single infusion of Amtagvi demonstrated a 31.4% objective response ...

The common effect through all these breakpoint variants is the formation of an oncogenic BRAF–KIAA1549 fusion incorporating the BRAF kinase domain, but lacking the amino-localized autoinhibitory ...

BRAF mutations are DNA changes in some cancer cells that can be treated with newer targeted therapies. BRAF mutations are found in roughly half of melanomas. Medications that target these mutations ...

Mutations in the BRAF gene can cause normal cells to become cancerous. BRAF mutations are most commonly found in melanomas, but can occur in other forms of cancer. Not all mutations in BRAF cause ...

Median time to response was 5.3 months (range: 1.6, 11.2). Among patients with BRAF fusion or rearrangement (n=64), the ORR was 52%. In patients with BRAF V600E mutation (n=12), the ORR was 50%.

The nod sanctions the type 2 RAF inhibitor to be used in tumors with a BRAF fusion or rearrangement, or BRAF V600 mutation. The go-ahead puts Ojemda toe to toe with Novartis’ Tafinlar-Mekinist ...

First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF ...

OJEMDA is indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 ...